Our pipeline focuses primarily on the Anti-Infective, Cardiovascular, and Central Nervous System therapeutic categories, and we are beginning to develop a presence in Anti-Neoplastics & Immunomodulating Agents and Dermatology.

The 32 products pending approval in our Generic business fall primarily in the CNS, Anti-Infective and Cardiovascular therapeutic categories.

In the MENA Region, our Branded business has 27 new products pending approval, including products in the Dermatological, CNS and Cardiovascular areas.

In our Injectable pipeline, which is our most extensive, we have 45 new products pending approval and 18 products under development. In this segment, we see exciting opportunities in the CNS, Anti-Infective and Cardiovascular therapeutic areas.

As of 31 December 2007, we had a total of 133 new products under development, the majority of which should receive several marketing authorisations, including separate marketing authorisations in differing strengths and/or product forms between 2009 and 2011.